Skip to content
value.today

Obalon Therapeutics Inc.

🇺🇸 San Diego, California, USABiotechnologyFounded 2008
Total raised
$39 M
4 rounds on record
Latest round
$16 M
Aug 2014
First round on record
Feb 2012
Today
Went public
See the company page

Obalon Therapeutics Inc. is listed today as Vyome Holdings, Inc: market value, financials and filings are on its company page.

Funding rounds

4 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Obalon Therapeutics Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Aug 2018$10 MPrivate placement after listing$10 to $50 million

Obalon Therapeutics Inc.: Private sale, Aug 2018

Investors in this round

21 investors had bought by the notice of Aug 29, 2018: 21 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 4 investors are named for Obalon Therapeutics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$10 M of $10 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Andrew Rasdal · Executive Officer, Director · President and Chief Executive Officer
  • Kelly J. Huang, Ph.D. · Executive Officer · Chief Operating Officer
  • Mark J. Brister · Executive Officer · Chief Technology Officer
  • William J. Plovanic · Executive Officer · Chief Financial Officer
  • David J. Moatazedi · Director
  • Douglas J. Fisher · Director
  • Kim J. Kamdar, Ph.D. · Director
  • Les J. Howe · Director
  • Raymond J. Dittamore · Director
  • Sharon J. Stevenson, DVM Ph.D. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Andrew Rasdal, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Aug 29, 2018. Read the notice at the SEC.

equitySEC
Aug 2014$16 MNo. 4$10 to $50 million

Obalon Therapeutics Inc.: Raise no. 4, Aug 2014

Investors in this round

5 investors had bought by the notice of Oct 2, 2014: 5 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 4 investors are named for Obalon Therapeutics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$16 M of $30 M offered; $14 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Andrew Rasdal · Executive Officer, Director
  • Doug Puloma Fisher · Director
  • Kim Puloma Kamdar · Director
  • Sharon Puloma Stevenson · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Andrew Rasdal, President. Source: SEC Form D, newest notice filed Oct 2, 2014. Read the notice at the SEC.

equitySEC
Dec 2012$5 MNo. 3$2 to $10 million

Obalon Therapeutics Inc.: Raise no. 3, Dec 2012

Investors in this round

1 investor had bought by the notice of Dec 19, 2012: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 4 investors are named for Obalon Therapeutics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$5 M of $5 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Andrew Rasdal · Executive Officer, Director
  • Doug Puloma Fisher · Director
  • Kim Puloma Kamdar · Director
  • Sharon Puloma Stevenson · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Andrew Rasdal, President. Source: SEC Form D, newest notice filed Dec 19, 2012. Read the notice at the SEC.

equitySEC
May 2012$17 MNo. 2$10 to $50 million

Obalon Therapeutics Inc.: Raise no. 2, May 2012

Investors in this round

3 investors had bought by the notice of May 17, 2012: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 4 investors are named for Obalon Therapeutics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$17 M of $17 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Andrew Rasdal · Executive Officer, Director
  • Kim Puloma Kamdar · Executive Officer, Director
  • Doug Puloma Fisher · Director
  • Sharon Puloma Stevenson · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Andrew Rasdal, President. Source: SEC Form D, newest notice filed May 17, 2012. Read the notice at the SEC.

equitySEC
Feb 2012$2 MNo. 1Under $2 million

Obalon Therapeutics Inc.: Raise no. 1, Feb 2012

Investors in this round

2 investors had bought by the notice of Mar 26, 2012: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 4 investors are named for Obalon Therapeutics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Andrew Rasdal · Executive Officer, Director
  • Douglas C. Puloma Sampson · Director
  • Kim Puloma Kamdar · Director
  • Sharon Puloma Stevenson · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Andrew Rasdal, President. Source: SEC Form D, newest notice filed Mar 26, 2012. Read the notice at the SEC.

debt, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • As the listed company Vyome Holdings, Inc, its revenue in fiscal 2025 came from these product and service lines: Licensing and milestone fees – Luliconazole $120,000 (37%), Royalty income related to above product sales $30,000 (9%).

    Annual report (SEC XBRL) · Dec 2025

  • Obalon Therapeutics Inc. chose not to state its revenue in its newest notice of a funding round (Aug 2018).

    SEC Form D · Aug 2018

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Aug 2018

Products and services#

No products or services of Obalon Therapeutics Inc. are on record.

Investors#

4 named in official filings. Open an investor to see everything it has backed.

Investors in Obalon Therapeutics Inc.
InvestorKindAmountRoundRoleSource
Domain Parters VII L.P.Fund or asset managernot statednot statedHeld Series A, B, C, D and E preferred stock, 10% owner (Form 3, 2016)SEC Form 3
DP VII Associates LPFund or asset managernot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2016)SEC Form 3
InterWest Management Partners X, LLCFund or asset managernot statednot statedHeld Series C, D and E preferred stock, 10% owner (Form 3, 2016)SEC Form 3
Interwest Partners X LPFund or asset managernot statednot statedHeld Series C, D and E preferred stock, 10% owner (Form 3, 2016)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 5 investors.

Largest shareholders today

Institutions holding Vyome Holdings, Inc shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Obalon Therapeutics Inc.
NameRoleNamed in
Andrew RasdalPresident and Chief Executive OfficerAug 2018
Kelly J. Huang, Ph.D.Chief Operating OfficerAug 2018
Mark J. BristerChief Technology OfficerAug 2018
William J. PlovanicChief Financial OfficerAug 2018
Kim Puloma KamdarExecutive officerMay 2012
Andrew RasdalPresident and Chief Executive OfficerAug 2018
David J. MoatazediDirectorAug 2018
Douglas J. FisherDirectorAug 2018
Kim J. Kamdar, Ph.D.DirectorAug 2018
Les J. HoweDirectorAug 2018
Raymond J. DittamoreDirectorAug 2018
Sharon J. Stevenson, DVM Ph.D.DirectorAug 2018
Doug Puloma FisherDirectorOct 2014
Kim Puloma KamdarDirectorOct 2014
Sharon Puloma StevensonDirectorOct 2014
Douglas C. Puloma SampsonDirectorMar 2012

Went public since 2016. Its SEC number is that of a company listed on a stock exchange.